A complete application in a minute — tailored resume and cover letter, ready to send.
The Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration in Silver Spring, MD invites a doctoral candidate to a fully funded ORISE fellowship.
You will work on immunological characterization of allergenic products, in vitro and in vivo assay development, and biomarker validation to support regulatory decision-making for diagnostics and therapies. Anticipated start is flexible; appointment is for one year with potential renewal.
U.S. Food and Drug Administration (FDA)
FDA-CBER-2026-0086
10/9/2026 3:00:00 PM Eastern Time Zone
A research opportunity is currently available at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) located in Silver Spring, Maryland.
The Center for Biologics Evaluation and Research (CBER) is one Center within the Food and Drug Administration, an Agency within the United States Government's Department of Health and Human Services. CBER's mission is to protect and enhance the public health through the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies.
This project will establish science-based approaches for immunological characterization of allergenic products and evaluation of food allergy immunotherapies. Through in vitro immunoassay development, analysis of immune responses to allergenic products, biomarker validation, and assessment of immunotherapy mechanisms, the project will generate evidence that supports risk assessment, product standardization, and regulatory decision-making for food allergy diagnostics and therapeutics. Currently, the lack of standardized immunological assays and validated biomarkers limits the ability to assess allergenic product consistency, predict immunotherapy outcomes, and evaluate safety and efficacy of emerging treatments. This research aims to improve FDA-regulated product quality, safety, and efficacy for individuals with IgE-mediated food allergies requiring diagnostic or therapeutic intervention.
These projects will generate data on excipient immunogenicity, IgE-based biomarkers, and innovative therapeutic mechanisms, supporting regulatory evaluation of food allergy diagnostics and treatments.
You will develop understanding of immunological principles underlying food allergy and allergenic product characterization. Through hands‑on laboratory experience, you will gain proficiency in advanced immunological assays including ELISA-based potency testing, modification-resolved IgE analysis, and cellular/tissue immunogenicity assessments using flow cytometry and super-resolution microscopy. You will learn to apply bioinformatic and statistical tools to analyze immunological datasets including DNA/RNA sequencing and mass spectrometry and interpret biomarker profiles. Training will include structured mentorship, laboratory research, seminars, and engagement with FDA's scientific community. You will apply acquired knowledge to support regulatory science and gain communication skills through scholarly publications and scientific presentations. This experience offers valuable exposure to FDA operations.
The mentor for this opportunity is Alexander S. Zhovmer (Alexander.Zhovmer@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentor.
Start date is flexible and will depend on a variety of factors.
The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.
The appointment is full time.
The participant will receive a monthly stipend commensurate with educational level and experience.
This opportunity is available to U.S. citizens and Lawful Permanent Residents (LPR) only.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on‑boarded at FDA. OPM can complete a background investigation only for individuals, including non‑US Citizens, who have resided in the US for a total of three of the past five years.
If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
The qualified candidate should be currently pursuing or have received a doctoral degree in the one of the relevant fields.
Richard
I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)
and
I have read the FDA Ethics Requirements.